Comparison of the spread of three botulinum toxin type A preparations

Archives of Dermatological Research

Volumn 304, Issue 2, 2012, Pages 155-161

  Kerscher, Martina ^a   Roll, Susanna ^b   Becker, Andreas ^b   Wigger Alberti, Walter ^c  

^a UNIVERSITY OF HAMBURG   (Germany)

^b MERZ PHARMACEUTICALS GMBH   (Germany)

^c Bioskin GmbH   (Germany)

Author keywords

Anhidrosis; Botulinum; Botulinum toxin type A; Esthetic; IncobotulinumtoxinA; NT 201; Spread

Indexed keywords

BOTULINUM TOXIN A;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DIFFUSION; DRUG SPREAD; DRUG TOLERABILITY; ESTHETICS; FEMALE; FOREHEAD; HUMAN; HUMAN EXPERIMENT; INJECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; AGED; BOTULINUM TOXINS, TYPE A; FEMALE; FOREHEAD; HUMANS; HYPOHIDROSIS; MIDDLE AGED; SKIN AGING; YOUNG ADULT;

EID: 84857905202     PISSN: 03403696     EISSN: 1432069X     Source Type: Journal    
DOI: 10.1007/s00403-011-1179-z     Document Type: Article

References (25)

1. Ascher B, Zakine B, Kestemont P, Baspeyras M, Bougara A, Santini J (2004) A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 51:223-233
2. Ascher B, Rzany BJ, Grover R (2009) Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. Dermatol Surg 35:1478-1486
3. Benecke R, Jost W, Kanovsky P, Ruzicka E, Comes G, Grafe S (2005) A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 64:1949-1951 (Pubitemid 40800714)
4. Carruthers A, Kiene K, Carruthers J (1996) Botulinum A exotoxin use in clinical dermatology. J Am Acad Dermatol 34:788-797 (Pubitemid 26137205)
5. Carruthers A, Carruthers J (2008) Botulinum toxin products overview. Skin Ther Lett 13:1-5
6. Carruthers JA, Lowe NJ, Menter MA, Gibson J, Nordquist M, Mordaunt J, Walker P, Eadie N (2002) A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 46:840-849
7. Cliff SH, Judodihardjo H, Eltringham E (2008) Different formulations of botulinum toxin type A have different migration characteristics: a double-blind, randomized study. J Cosmet Dermatol 7:50-54 (Pubitemid 351228167)
8. de Almeida AT, De Boulle KJ (2007) Diffusion characteristics of botulinum neurotoxin products and their clinical significance in cosmetic applications. J Cosmet Laser Ther 9(Suppl 1):17-22
9. De Boulle K, Fragien S, Sommer B, Glogau R (2010) Treating glabellar lines with botulinum toxin type-A-hemagglutinin complex: a review of the science, the clinical data, and patient satisfaction. Clin Interv Aging 5:101-118
10. De Maio M, Rzany B (2007) Botulinum toxin in aesthetic medicine. Springer, Heidelberg, Germany
11. Dressler D, Benecke R (2007) Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil 29:1761-1768 (Pubitemid 350176807)
12. Eisele KH, Fink K, Vey M, Taylor HV (2011) Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon 57:555-565
13. Hexsel D, Dal'Forno T, Hexsel C, Do Prado DZ, Lima MM (2008) A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type A. Dermatol Sur 34:52-59 (Pubitemid 350308586)
14. Hsu TS, Dover JS, Arndt KA (2004) Effect of volume and concentration on the diffusion of botulinum exotoxin A. Arch Dermatol 140:1351-1354 (Pubitemid 39473635)
15. Inoue K, Fujinaga Y, Watanabe T, Ohyama T, Takeshi K, Moriishi K, Nakajima H, Inoue K, Oguma K (1996) Molecular composition of Clostridium botulinum type A progenitor toxins. Infect Immun 64:1589-1594 (Pubitemid 26129820)
16. Jost WH, Kohl A, Brinkmann S, Comes G (2005) Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (Botox®) in healthy volunteers. J Neural Transm 112:905-913 (Pubitemid 40869079)
17. Kanovský P, Slawek J, Denes Z, Platz T, Sassin I, Comes G, Grafe S (2009) Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin Neuropharmacol 32:259-265
18. Karsai S, Raulin C (2009) Current evidence on the unit equivalence of different botulinum neurotoxin A formulations and recommendations for clinical practice in dermatology. Dermatol Surg 35:1-8
19. Klein A, Carruthers A, Fagien S, Lowe NJ (2008) Comparisons among botulinum toxins: an evidence-based review. Plast Reconstr Surg 121:413e-422e
20. Lowe NJ, Ascher B, Heckmann M, Kumar C, Fraczek S, Eadie N (2005) Double-blind, randomised, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet. Dermatol Surg 31:257-262 (Pubitemid 43072975)
21. Minor V (1928) Ein neues verfahren zu der klinischen untersuchung der schweibabsonderung. Deutsch Z Nervenhlk 101:302-308
22. Monheit G, Carruthers A, Brandt F, Rand R (2007) A randomised, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg 33:S51-S59 (Pubitemid 46051400)
23. Roggenkämper P, Jost W, Bihari K, Comes G, Grafe S (2006) Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 113:303-312 (Pubitemid 43201097)
24. Trindade de Almeida AR, Marques E, de Almeida J, Cunha T, Boraso R (2007) Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg 33:S37-S43 (Pubitemid 46051398)
25. Wohlfarth K, Muller C, Sassin I, Comes G, Grafe S (2007) Neurophysiological double-blind trial of a botulinum neurotoxin type A free of complexing proteins. Clin Neuropharmacol 30:86-94 (Pubitemid 46581201)